Prediction models for biochemical failure after FS-HDR-BT 179 19. Maenhout M, Peters M, van Vulpen M, Moerland MA, Meijer RP, van den Bosch MAAJ, et al. Focal MRIGuided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Technol Cancer Res Treat 2017;16:1194–201. 20. Grignon DJ, Sakr WA. Histologic effects of radiation therapy and total androgen blockade on prostate cancer. Cancer 1995;75:1837–41. 21. Crook JM, Bahadur YA, Robertson SJ, Perry GA, Esche BA. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 1997;79:81–9. 22. Goldstein NS, Martinez A, Vicini F, Stromberg J. The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost: Correlation with biochemical failure. Am J Clin Pathol 1998;110:765–75. 23. Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:31–9. 24. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355–67. 25. Riley RD, Ensor J, Snell KIE, Harrell FE, Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ 2020;368:1–12. 26. White IR, Royston P. Imputing missing covariate values for the Cox model. Stastics Med 2009;28:1982– 1998. 27. Moons KGM, Donders RART, Stijnen T, Harrell FE. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol 2006;59:1092–101. 28. Nieboer D, Vergouwe Y, Roobol MJ, Ankerst DP, Kattan MW, Vickers AJ, et al. Nonlinear modeling was applied thoughtfully for risk prediction: The Prostate Biopsy Collaborative Group. J Clin Epidemiol 2015;68:426–34. 29. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): Explanation and elaboration. Ann Intern Med 2015;162:W1–73. 30. Team RC. R: A language and environment for statistical computing 2019. 31. Ray ME, Thames HD, Levy LB, Horwitz EM, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006;64:1140–50. 32. Spiess PE, Katz AE, Chin JL, Bahn D, Cohen JK, Shinohara K, et al. A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU Int 2010;106:194–8. 33. Spiess PE, Levy DA, Mouraviev V, Pisters LL, Jones JS. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: A novel risk stratification model. BJU Int 2013;112:256–61. 34. Shah TT, Peters M, Kanthabalan A, McCartan N, Fatola Y, Van Der Voort Van Zyp J, et al. PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure. Prostate Cancer Prostatic Dis 2016;19:311–6. 35. Morton G, McGuffin M, Chung HT, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 2020;146:90–6. 36. Murgic J, Morton G, Loblaw A, D’Alimonte L, Ravi A, Wronski M, et al. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. Int J Radiat Oncol Biol Phys 2018;102:561–7. 37. Jiang P, van der Horst C, Kimmig B, Zinsser F, Poppe B, Luetzen U, et al. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome. Brachytherapy 2017;16:186–92. 38. Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, et al. [ 68 Ga- ] PSMA-11 PET / CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard – Implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol 2019;d:7– 12. 8
RkJQdWJsaXNoZXIy MTk4NDMw